# News Release

## Santen Updates Pipeline in Corporate Presentation of January 8, 2019

**January 8, 2019** - Santen Pharmaceutical Co., Ltd. (Head Office: Osaka; hereinafter, “Santen”) today updated the description of status of certain pipeline projects in corporate presentation as attached.

The impact of these changes on Santen’s published forecasts for the fiscal year ending March 31, 2019 is not material.

**About Santen**

As a specialized company dedicated to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices. Santen is the market leader for prescription ophthalmic pharmaceuticals in Japan and its products now reach patients in over 60 countries. With scientific knowledge and organizational capabilities nurtured over a nearly 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society. For more information, please visit Santen’s website (www.santen.com).

**Forward-looking Statements**

Information provided in this pipeline contains forward-looking statements. The achievement of these forecasts is subject to risk and uncertainty from various sources. Therefore, please note that the actual results may differ significantly from the forecasts. Business performance and financial conditions are subject to the effects of changes in regulations made by the governments of Japan and other nations concerning medical insurance, drug pricing and other systems, and to fluctuations in market variables such as interest rates and foreign exchange rates.

**Contact**

Christopher Hohman
Corporate Communications Group
Santen Pharmaceutical Co., Ltd.
E-mail: ir@santen.com, Tel: +81-6-4802-9360

# Pipeline / Product Development Status (1)

As of January 8, 2019

| | Indication | Region | Status |
|---|---|---|---|
| **DE-117**<br>*EYBELIS*<br>EP2 receptor agonist | Glaucoma / ocular hypertension | US | P3<br>*Plan: Jan~Jun 2020 P3 completion* |
| | | Japan | Launched in Nov 2018 |
| | | Asia | P3<br>*Plan: 2nd half FY2018 P3 completion* |
| **DE-126**<br>FP/EP3 receptors dual agonist | Glaucoma / ocular hypertension | US | P2b |
| | | Japan | |
| **DE-128**<br>*PreserFlo*[1] | Glaucoma | US | P2/3<br>*Plan: calendar 2019 PMA rolling submission completion, calendar 2020 launch* |
| | | Europe | CE mark granted |
| **DE-109**<br>IVT sirolimus | Uveitis | US | P3 (LUMINA trial started in Dec 2018)<br>*Plan: Jan~Jun 2021 P3 completion* |
| | | Japan | P3 |
| | | Europe | P3 |
| | | Asia | Filed |
| **DE-122**<br>Anti-endoglin antibody | Wet age-related macular degeneration | US | P2a<br>*Plan: Jan~Jun 2019 P2a completion* |

[1]PreserFlo is the new name of the pipeline project which has been known by the development code DE-128 and/or trade name *InnFocus MicroShunt* in Europe.

Updated information is underlined.

# Pipeline / Product Development Status (2)

As of January 8, 2019

| | Indication | Region | Status |
|---|---|---|---|
| **DE-089**<br>*Diquas* | Dry eye | China | Launched |
| **DE-076B**<br>Cyclokat / *Ikervis* ciclosporin | Severe keratitis in patients with dry eye | Asia | Launched |
| | | US | P2 |
| **DE-076C**<br>Vekacia / *Verkazia* ciclosporin | Vernal kerato-conjunctivits | Europe | Launched |
| | | Others | Approved in Dec 2018 in Canada<br>*Plan: calendar 2019 launch* |
| **DE-114A**<br>epinastine HCl (high dose) | Allergic conjunctivitis | Japan | Filed<br>*Plan: Jul~Dec 2019 approval* |
| **DE-127**<br>atropine sulfate | Myopia | Asia | P2<br>*Plan: 2nd half of FY2019 P2 completion* |

Updated information is underlined.